Blood test combo flags inflammation, organ damage in IgG4-RD
Measuring IgG1 and IgG4 helps physicians gauge high-risk cases early
Written by |
Elevated blood levels of an antibody called IgG1, measured alongside a specific ratio to IgG4, can help identify a more severe form of IgG4-related disease (IgG4-RD) marked by widespread organ damage, a new study shows.
Because the severity of IgG4-RD varies widely from person to person, researchers say evaluating these two immune markers together could give doctors a clearer way to spot high-risk patients early and tailor treatment before severe organ damage occurs.
The study, “Elevated serum IgG1, complement activation, and clinical severity in IgG4-related disease: a comprehensive subgroup analysis,” was published in Clinical Rheumatology.
In IgG4-RD, overactive immune cells form tumor-like masses that cause swelling, inflammation, and scarring (fibrosis) across multiple organs. Specialized immune cells called plasma cells, which produce IgG4 antibodies, are found in high numbers in affected tissues. In fact, testing for elevated IgG4 levels in the blood is a standard diagnostic tool for the condition.
While IgG4 is the classic hallmark of the disease, studies suggest that IgG1 antibodies — the body’s most common antibody class — may actually drive the destructive inflammatory injury. Overall, high IgG1 levels may signal a more aggressive pattern of immune activation in diseases characterized by inflammation and scarring.
Uncovering a clearer marker for disease severity
Despite its potential role in driving inflammation, using IgG1 levels to organize patients into distinct risk categories had not been tested. Identifying reliable risk markers is important because IgG4-RD affects each patient differently.
To investigate, researchers in China analyzed the medical records of 344 adults with newly diagnosed, untreated IgG4-RD. Their goal was to determine whether combining IgG1 and IgG4 measurements could create a reliable scoring tool for gauging disease severity.
Blood tests revealed that nearly 40% of patients had IgG1 levels above the normal limit.
When comparing patient groups, the researchers found that those with elevated IgG1 were typically older, more often male, and had significantly more organs affected. This group showed higher overall disease activity, with lung, kidney, and liver involvement occurring more frequently.
Patients with high IgG1 also showed notably lower levels of key immune proteins called C3 and C4. These proteins belong to the complement cascade, a system that helps clear infections and inflammatory debris. Low complement levels (hypocomplementemia) are a known sign of active, severe inflammation in IgG4-RD.
Across all participants, higher IgG1 levels consistently paired with higher total antibodies (IgG, IgG3, and IgG4), elevated inflammatory markers like ESR, and lower protective complement proteins (C3).
To refine their scoring method, the researchers split patients into four groups based on their IgG1 levels and the IgG1-to-IgG4 ratio, with a ratio above 1 indicating “IgG1 dominance”:
- Elevated IgG1 without IgG1 dominance (19% of patients): This group was predominantly male and had the most severe disease profile, showing the highest disease activity scores, the highest IgG4 levels, the most organ damage, and the lowest C3 and C4 protein levels.
- Non-elevated IgG1 with IgG1 dominance (33.5% of patients): This group had the mildest disease profile, with the lowest disease activity scores and the fewest affected organs.
- Elevated IgG1 with IgG1 dominance
- Non-elevated IgG1 without IgG1 dominance
After adjusting for age and sex, elevated IgG1 remained a strong, independent predictor of low complement levels, high disease activity, and severe lung and kidney involvement.
The team also uncovered striking differences between sexes. In men, high IgG1 strongly correlated with older age, severe inflammation, and low complement proteins. In women, these links were markedly weaker.
“These findings position the combined assessment of IgG1 and IgG4 as a potential tool for risk stratification, offering a refined framework to decipher the [variability] of IgG4-RD,” the researchers wrote.
Leave a comment
Fill in the required fields to post. Your email address will not be published.